I just came across an investment opportunity in the medical device sector and want to discuss the company Medtronic with everyone.

Honestly, in the medical device track, I’ve always paid close attention to companies involved in robotic surgical systems. Intuitive Surgical has performed well over the years, but its stock price is indeed a bit expensive. However, Medtronic is also making efforts in this direction, and its valuation looks more attractive — the recent forward P/E ratio is 16.3, below the five-year average of 16.7.

Why am I optimistic about this MDT medical device giant? Several reasons. First is its dividend record. The company has increased dividends for 48 consecutive years, with a recent yield of around 2.9%. This isn’t just a good-looking number; it reflects a well-managed company capable of consistently generating returns for shareholders over decades. Its payout ratio is about 79%, leaving room for growth, indicating that dividends are sustainable.

Looking at the company’s innovation investment, Medtronic has deployed over 13,600 scientists and engineers across more than 150 countries, holding over 41,000 active patents. It spends $270 million annually on R&D, covering fields like surgery, endoscopy, cardiac ablation, neurovascular, and neuromodulation. Such scale of investment is no joke.

Recently, it’s even more interesting that the company received FDA approval for the Hugo robotic surgical system. Meanwhile, to focus on faster-growing businesses, Medtronic spun off its diabetes division, which is valued at nearly $8 billion. This decision is smart — shedding relatively mature businesses to concentrate resources on more promising areas.

According to the latest financial report, Q3 revenue grew 8.7% year-over-year, which is quite good for a company of this size. The CEO also emphasized confidence in achieving long-term growth through innovation pipelines and product breadth during the earnings call.

Overall, this medical device company has both stable dividend flows and genuine growth momentum. If you’re looking for a long-term hold that offers both growth and dividends, Medtronic is definitely worth paying attention to. I’ve added it to my watchlist.